July 6 (Reuters) - Immunovaccine Inc IMV.TO
* Immunovaccine announces positive interim phase 1 data for
Depovax-based respiratory syncytial virus vaccine candidate
* Safety analysis indicates that DPX-RSV was well tolerated
among all study participants, with no serious adverse events
recorded
* Analysis provides rationale to continue clinical testing
of DPX-RSV in future human trials
* Immunovaccine announces positive interim phase 1 data for
Depovax-based respiratory syncytial virus vaccine candidate
Source text for Eikon: ID:nMKWbPHswa
Further company coverage: IMV.TO